Bioxodes
Private Company
Funding information not available
Overview
Bioxodes is a Belgian biotech focused on addressing significant unmet needs in stroke, particularly intracerebral hemorrhage (ICH), which currently has no approved therapy. Its lead asset, BIOX-101, is a first-in-class drug with a dual mechanism inhibiting neutrophil extracellular traps (NETs) and coagulation factors XIa/XIIa, aiming to prevent secondary damage without increasing bleeding risk. The company is preparing for a potentially pivotal Phase 2b trial in ICH and exploring expansion into ischemic stroke and other chronic inflammatory conditions. With Orphan Drug Designation in the US and EU, Bioxodes is positioning its novel platform as a breakthrough in thrombo-inflammation.
Technology Platform
Platform based on recombinant protein Ir-CPI (BIOX-101) with dual mechanism: inhibits neutrophil activation/Neutrophil Extracellular Traps (NETs) and coagulation factors XIa/XIIa, aiming to prevent thrombosis and inflammation without increasing bleeding risk.
Opportunities
Risk Factors
Competitive Landscape
Competitors include companies developing Factor XIa inhibitors (e.g., Bayer, BMS, Anthos Therapeutics) for safer anticoagulation, and biotechs targeting NETosis or neuroinflammation. Bioxodes's key differentiation is the combined inhibition of both the coagulation (FXIa/FXIIa) and inflammatory (NETs) pathways in a single agent, with early clinical data suggesting no increased bleeding.